Objective To analyze the clinicopathological features and survival conditions of human epidermal growth factor receptor-2(Her-2)negative and low-expression breast cancer.Methods Aretrospective analysis was performed for the clinicopatho-logical and prognostic survival data of 327 patients of Her-2 negative or low-expression breast cancer who visited the First Affiliated Hospital of Xinjiang Medical University from April 2013 to November 2022,and were divided into the Her-2 low-expression group(n=217)and the Her-2 negative group(n=110).The clinicopathological features,and prognostic survival indicators such as recur-rence and metastasis after treatment,mortality,overall survival,and progression-free survival of the two groups were compared.Accord-ing to the hormone receptor(HR)status,the patients were divided into HR+and HR-cohorts,and the progression-free survival of patients with Her-2 negative or low-expression breast cancer in the two cohorts was compared.Results Breast cancer with Her-2 low-expression accounted for a high proportion in the clinic,most of them were estrogen receptor(ER)-positive manifested as Luminal type,the pathological prognosis stage was mostly stage Ⅰ,and ki-67 was low expression.However,Her-2 negative breast cancer was often combined with ER-negative manifestations as triple-negative type,the pathological prognosis stage was mostly stage Ⅲ,and ki-67 was highly expression,and more brain metastases and/or other organ metastases appeared after treatment,all the differences were sta-tistically significant(P＜0.05).However,There were no statistical differences in mortality,overall survival,and progression-free sur-vival between groups and the two cohorts(P＞0.05).Conclusion There is tumor heterogeneity between Her-2 negative and low-ex-pression breast cancer,Her-2 low-expression breast cancer has the advantages of high ER positive rate,low ki-67 expression,and early stage of pathological prognosis and stage,and the metastasis rate of the brain metastases and/or other organs is relatively low after treatment,but it has not converted into significant survival benefits.